Apollon Wealth Management LLC Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)

Apollon Wealth Management LLC grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 75,085 shares of the biopharmaceutical company’s stock after acquiring an additional 4,321 shares during the quarter. Apollon Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $3,885,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Jeppson Wealth Management LLC raised its stake in shares of Bristol-Myers Squibb by 2.3% in the third quarter. Jeppson Wealth Management LLC now owns 15,063 shares of the biopharmaceutical company’s stock worth $779,000 after purchasing an additional 334 shares during the last quarter. Opinicus Capital Inc. raised its position in Bristol-Myers Squibb by 8.1% in the 3rd quarter. Opinicus Capital Inc. now owns 17,334 shares of the biopharmaceutical company’s stock worth $897,000 after buying an additional 1,294 shares during the last quarter. Versor Investments LP lifted its stake in Bristol-Myers Squibb by 13.9% during the 3rd quarter. Versor Investments LP now owns 23,800 shares of the biopharmaceutical company’s stock valued at $1,231,000 after acquiring an additional 2,900 shares during the period. Venturi Wealth Management LLC grew its stake in shares of Bristol-Myers Squibb by 116.3% in the third quarter. Venturi Wealth Management LLC now owns 2,898 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 1,558 shares during the period. Finally, Jaffetilchin Investment Partners LLC raised its holdings in shares of Bristol-Myers Squibb by 4.0% during the third quarter. Jaffetilchin Investment Partners LLC now owns 10,308 shares of the biopharmaceutical company’s stock valued at $533,000 after purchasing an additional 393 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Jefferies Financial Group raised their target price on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday, August 28th. TD Cowen lifted their price objective on Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Barclays increased their target price on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a report on Monday, October 7th. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $50.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, October 18th. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $54.07.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat bought 1,830 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average cost of $54.67 per share, with a total value of $100,046.10. Following the transaction, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at approximately $3,395,499.03. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total value of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares in the company, valued at $654,091.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Samit Hirawat purchased 1,830 shares of the company’s stock in a transaction on Friday, November 1st. The shares were purchased at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the purchase, the executive vice president now owns 62,109 shares in the company, valued at approximately $3,395,499.03. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Price Performance

NYSE:BMY opened at $59.02 on Wednesday. The business’s 50-day simple moving average is $52.07 and its two-hundred day simple moving average is $46.89. The stock has a market cap of $119.70 billion, a PE ratio of -16.44, a P/E/G ratio of 20.09 and a beta of 0.44. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to the consensus estimate of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. During the same period in the previous year, the business earned $2.00 earnings per share. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. As a group, analysts forecast that Bristol-Myers Squibb will post 0.92 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.07%. The ex-dividend date of this dividend was Friday, October 4th. Bristol-Myers Squibb’s payout ratio is currently -66.85%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.